Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos Principais

SML0700

Sigma-Aldrich

FTY720

≥98% (HPLC), powder, immunomodulating drug

Sinônimo(s):

2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride, Fingolimod hydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(2)

About This Item

Fórmula empírica (Notação de Hill):
C19H33NO2 · HCl
Número CAS:
162359-56-0
Peso molecular:
343.93
Código UNSPSC:
12352211
NACRES:
NA.77

product name

FTY720, ≥98% (HPLC)

Nível de qualidade

100

Ensaio

≥98% (HPLC)

forma

powder

condição de armazenamento

desiccated

cor

white to beige

solubilidade

water: 10 mg/mL, clear

temperatura de armazenamento

−20°C

InChI

1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H

chave InChI

SWZTYAVBMYWFGS-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

FTY720 has been used as an immunomodulator and is used to investigate its effect on in vitro gastrulation model of P19C5 stem cells. It is also used to determine its efficacy in prolonging the survival corneal transplantation. FTY720 has been used to study its effect on the proliferation and differentiation of cultured embryonic hippocampal neural stem cells (NSCs) using the 5-bromo-2-deoxyuridine incorporation assay, the neurosphere formation assay and western blot analysis.

Ações bioquímicas/fisiológicas

FTY720 is an immunomodulating drug and sphingosine 1-phosphate (S1P) receptor modulator. Phosphorylation of FTY270 by sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph nodes, preventing them from taking part in an autoimmune response. Clinically, it has been approved for the treatment of multiple sclerosis (MS). It has also been shown to block and reverse paclitaxel-induced chemotherapy induced peripheral neuropathy (CIPN) through S1PR inhibition as well as inhibit the activity of histone deacetylases in the hippocampus of mouse brains, thereby modulating memory.

Pictogramas

Health hazard
GHS08

Palavra indicadora

Warning

Frases de perigo

H373

Declarações de precaução

P260 - P314 - P501

Classificações de perigo

STOT RE 2

Órgãos-alvo

Immune system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 2

1 of 2

W146 hydrate ≥98% (HPLC)

Sigma-Aldrich

W1020

W146 hydrate

Sphingosine 1-phosphate ≥98.0% (TLC)

Sigma-Aldrich

73914

Sphingosine 1-phosphate

Veronique E Miron et al.
Journal of the neurological sciences, 274(1-2), 13-17 (2008-08-06)
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue that is under investigation as a therapy for both relapsing-remitting (RR) and progressive forms of multiple sclerosis (MS). The demonstrated beneficial effect of FTY720 on disease activity in
Mohammad G Mohammad et al.
The Journal of clinical investigation, 124(3), 1228-1241 (2014-02-27)
In the CNS, no pathway dedicated to immune surveillance has been characterized for preventing the anti-CNS immune responses that develop in autoimmune neuroinflammatory disease. Here, we identified a pathway for immune cells to traffic from the brain that is associated
Darren Ruane et al.
The Journal of experimental medicine, 210(9), 1871-1888 (2013-08-21)
Developing efficacious vaccines against enteric diseases is a global challenge that requires a better understanding of cellular recruitment dynamics at the mucosal surfaces. The current paradigm of T cell homing to the gastrointestinal (GI) tract involves the induction of α4β7
Douglas Kazutoshi Sato et al.
Journal of neuroimmunology, 268(1-2), 95-98 (2014-02-11)
Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
Exibir todos os documentos relacionados

Conteúdo relacionado

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica